Longboard Pharmaceuticals Inc (LBPH)

$18.24

-0.69

(-3.65%)

Live

Insights on Longboard Pharmaceuticals Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 107.8%

Performance

  • $17.83
    $18.93
    $18.24
    downward going graph

    2.25%

    Downside

    Day's Volatility :5.81%

    Upside

    3.65%

    downward going graph
  • $3.60
    $28.15
    $18.24
    downward going graph

    80.26%

    Downside

    52 Weeks Volatility :87.21%

    Upside

    35.2%

    downward going graph

Returns

PeriodLongboard Pharmaceuticals IncIndex (Russel 2000)
3 Months
-11.83%
0.0%
6 Months
378.03%
0.0%
1 Year
167.0%
0.0%
3 Years
127.25%
-22.6%

Highlights

Market Capitalization
755.1M
Book Value
$8.07
Earnings Per Share (EPS)
-2.25
Wall Street Target Price
41.22
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.3%
Return On Equity TTM
-30.04%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-62.9M
Diluted Eps TTM
-2.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.86
EPS Estimate Next Year
-2.28
EPS Estimate Current Quarter
-0.49
EPS Estimate Next Quarter
-0.48

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Longboard Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 125.99%

Current $18.24
Target $41.22

Technicals Summary

Sell

Neutral

Buy

Longboard Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals Inc
-8.11%
378.03%
167.0%
127.25%
13.69%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals Inc
NA
NA
NA
-1.86
-0.3
-0.19
NA
8.07
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals Inc
Buy
$755.1M
13.69%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • Farallon Capital Management, L.L.C.

    14.89%
  • Cormorant Asset Management, LLC

    8.62%
  • T. Rowe Price Associates, Inc.

    5.70%
  • Vanguard Group Inc

    4.44%
  • FMR Inc

    4.24%
  • Polar Capital Holdings PLC

    3.36%

Company Information

longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.

Organization
Longboard Pharmaceuticals Inc
Employees
50
CEO
Mr. Kevin R. Lind
Industry
Miscellaneous

FAQs